Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
This list of potential positions covers Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools to further calibrate your research.
Story appears to be empty
Aduro Biotech (ADRO)
The firm beta is close to zero. As returns on the market increase, Aduro Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Aduro Biotech is expected to be smaller as well. The beta indicator helps investors understand whether Aduro Biotech moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Aduro deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The entity currently falls under 'Small-Cap' category with a current market capitalization of 236.61 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Aduro Biotech's market, we take the total number of its shares issued and multiply it by Aduro Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Ayala Pharmaceuticals (ADXS)
The company has return on total asset (ROA) of (24.13) % which means that it has lost $24.13 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (41.98) %, meaning that it created substantial loss on money invested by shareholders. Ayala Pharmaceuticals' management efficiency ratios could be used to measure how well Ayala Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The entity currently falls under 'Small-Cap' category with a current market capitalization of 247.58 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ayala Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Ayala Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
BeyondSpring (BYSI)
The entity has a beta of 0.8394. As returns on the market increase, BeyondSpring's returns are expected to increase less than the market. However, during the bear market, the loss of holding BeyondSpring is expected to be smaller as well. The beta indicator helps investors understand whether BeyondSpring moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if BeyondSpring deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The firm currently falls under 'Micro-Cap' category with a current market capitalization of 70.23 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BeyondSpring's market, we take the total number of its shares issued and multiply it by BeyondSpring's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Based on Macroaxis valuation methodology, the firm appears to be overvalued. BeyondSpring shows a prevailing Real Value of $1.45 per share. The current price of the firm is $1.8. Our model approximates the value of BeyondSpring from analyzing the firm fundamentals such as Return On Equity of -3.1, shares outstanding of 39.02 M, and Operating Margin of (15.41) % as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor purchasing undervalued instruments and trading away overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Blueprint Medicines Corp (BPMC)
The company has return on total asset (ROA) of (0.2534) % which means that it has lost $0.2534 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5714) %, meaning that it created substantial loss on money invested by shareholders. Blueprint Medicines' management efficiency ratios could be used to measure how well Blueprint Medicines manages its routine affairs as well as how well it operates its assets and liabilities. As of April 19, 2024, Return On Tangible Assets is expected to decline to -0.51. In addition to that, Return On Capital Employed is expected to decline to -0.61. At present, Blueprint Medicines' Other Current Assets are projected to decrease significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 613.2 M, whereas Total Assets are forecasted to decline to about 784.9 M. The firm currently falls under 'Mid-Cap' category with a current market capitalization of 5.44 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Blueprint Medicines's market, we take the total number of its shares issued and multiply it by Blueprint Medicines's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Short Long Term Debt Total
812.83 Million
At present, Blueprint Medicines' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting.
CytomX Therapeutics (CTMX)
The company has return on total asset (ROA) of (0.0175) % which means that it has lost $0.0175 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (54.7503) %, meaning that it created substantial loss on money invested by shareholders. CytomX Therapeutics' management efficiency ratios could be used to measure how well CytomX Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.01 in 2024, whereas Return On Tangible Assets are likely to drop (0) in 2024. At this time, CytomX Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 5.2 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 19.8 M in 2024. The firm currently falls under 'Small-Cap' category with a current market capitalization of 117.18 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate CytomX Therapeutics's market, we take the total number of its shares issued and multiply it by CytomX Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Deciphera Pharmaceuticals LLC (DCPH)
The company has return on total asset (ROA) of (0.2843) % which means that it has lost $0.2843 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5629) %, meaning that it created substantial loss on money invested by shareholders. Deciphera Pharmaceuticals' management efficiency ratios could be used to measure how well Deciphera Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.43. The current Return On Capital Employed is estimated to decrease to -0.59. As of now, Deciphera Pharmaceuticals' Fixed Asset Turnover is increasing as compared to previous years. The Deciphera Pharmaceuticals' current Asset Turnover is estimated to increase to 0.36, while Total Assets are projected to decrease to under 393.8 M. The firm currently falls under 'Mid-Cap' category with a current market capitalization of 1.15 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Deciphera Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Deciphera Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The company has return on total asset (ROA) of (0.1596) % which means that it has lost $0.1596 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9213) %, meaning that it created substantial loss on money invested by shareholders. G1 Therapeutics' management efficiency ratios could be used to measure how well G1 Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.41 in 2024. Return On Capital Employed is likely to drop to -0.45 in 2024. At this time, G1 Therapeutics' Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 121 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 5.9 M in 2024. The firm currently falls under 'Small-Cap' category with a current market capitalization of 217.67 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate G1 Therapeutics's market, we take the total number of its shares issued and multiply it by G1 Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the entity appears to be undervalued. G1 Therapeutics owns a latest Real Value of $5.42 per share. The recent price of the entity is $4.17. Our model calculates the value of G1 Therapeutics from inspecting the entity fundamentals such as Return On Asset of -0.16, shares owned by insiders of 11.68 %, and Operating Margin of (0.60) % as well as reviewing its technical indicators and probability of bankruptcy. In general, most investors encourage acquiring undervalued equities and dropping overvalued equities since, sooner or later, asset prices and their ongoing real values will blend.
Macroaxis financial leverage refers to using borrowed capital as a funding source to finance Macroaxis ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Macroaxis financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Macroaxis' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Macroaxis' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Macroaxis's total debt and its cash.
Macroaxis Gross Profit
Macroaxis Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Macroaxis previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Macroaxis Gross Profit growth over the last 10 years. Please check Macroaxis' gross profit and other fundamental indicators for more details.
Story appears to be empty
Aduro Biotech (ADRO)
The firm beta is close to zero. As returns on the market increase, Aduro Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Aduro Biotech is expected to be smaller as well. The beta indicator helps investors understand whether Aduro Biotech moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Aduro deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The entity currently falls under 'Small-Cap' category with a current market capitalization of 236.61 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Aduro Biotech's market, we take the total number of its shares issued and multiply it by Aduro Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Ayala Pharmaceuticals (ADXS)
The company has return on total asset (ROA) of (24.13) % which means that it has lost $24.13 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (41.98) %, meaning that it created substantial loss on money invested by shareholders. Ayala Pharmaceuticals' management efficiency ratios could be used to measure how well Ayala Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The entity currently falls under 'Small-Cap' category with a current market capitalization of 247.58 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ayala Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Ayala Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
BeyondSpring (BYSI)
The entity has a beta of 0.8394. As returns on the market increase, BeyondSpring's returns are expected to increase less than the market. However, during the bear market, the loss of holding BeyondSpring is expected to be smaller as well. The beta indicator helps investors understand whether BeyondSpring moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if BeyondSpring deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The firm currently falls under 'Micro-Cap' category with a current market capitalization of 70.23 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BeyondSpring's market, we take the total number of its shares issued and multiply it by BeyondSpring's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Based on Macroaxis valuation methodology, the firm appears to be overvalued. BeyondSpring shows a prevailing Real Value of $1.45 per share. The current price of the firm is $1.8. Our model approximates the value of BeyondSpring from analyzing the firm fundamentals such as Return On Equity of -3.1, shares outstanding of 39.02 M, and Operating Margin of (15.41) % as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor purchasing undervalued instruments and trading away overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Blueprint Medicines Corp (BPMC)
The company has return on total asset (ROA) of (0.2534) % which means that it has lost $0.2534 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5714) %, meaning that it created substantial loss on money invested by shareholders. Blueprint Medicines' management efficiency ratios could be used to measure how well Blueprint Medicines manages its routine affairs as well as how well it operates its assets and liabilities. As of April 19, 2024, Return On Tangible Assets is expected to decline to -0.51. In addition to that, Return On Capital Employed is expected to decline to -0.61. At present, Blueprint Medicines' Other Current Assets are projected to decrease significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 613.2 M, whereas Total Assets are forecasted to decline to about 784.9 M. The firm currently falls under 'Mid-Cap' category with a current market capitalization of 5.44 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Blueprint Medicines's market, we take the total number of its shares issued and multiply it by Blueprint Medicines's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Short Long Term Debt Total
812.83 Million
At present, Blueprint Medicines' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting.
CytomX Therapeutics (CTMX)
The company has return on total asset (ROA) of (0.0175) % which means that it has lost $0.0175 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (54.7503) %, meaning that it created substantial loss on money invested by shareholders. CytomX Therapeutics' management efficiency ratios could be used to measure how well CytomX Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.01 in 2024, whereas Return On Tangible Assets are likely to drop (0) in 2024. At this time, CytomX Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 5.2 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 19.8 M in 2024. The firm currently falls under 'Small-Cap' category with a current market capitalization of 117.18 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate CytomX Therapeutics's market, we take the total number of its shares issued and multiply it by CytomX Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Deciphera Pharmaceuticals LLC (DCPH)
The company has return on total asset (ROA) of (0.2843) % which means that it has lost $0.2843 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5629) %, meaning that it created substantial loss on money invested by shareholders. Deciphera Pharmaceuticals' management efficiency ratios could be used to measure how well Deciphera Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.43. The current Return On Capital Employed is estimated to decrease to -0.59. As of now, Deciphera Pharmaceuticals' Fixed Asset Turnover is increasing as compared to previous years. The Deciphera Pharmaceuticals' current Asset Turnover is estimated to increase to 0.36, while Total Assets are projected to decrease to under 393.8 M. The firm currently falls under 'Mid-Cap' category with a current market capitalization of 1.15 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Deciphera Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Deciphera Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The company has return on total asset (ROA) of (0.1596) % which means that it has lost $0.1596 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9213) %, meaning that it created substantial loss on money invested by shareholders. G1 Therapeutics' management efficiency ratios could be used to measure how well G1 Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.41 in 2024. Return On Capital Employed is likely to drop to -0.45 in 2024. At this time, G1 Therapeutics' Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 121 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 5.9 M in 2024. The firm currently falls under 'Small-Cap' category with a current market capitalization of 217.67 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate G1 Therapeutics's market, we take the total number of its shares issued and multiply it by G1 Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the entity appears to be undervalued. G1 Therapeutics owns a latest Real Value of $5.42 per share. The recent price of the entity is $4.17. Our model calculates the value of G1 Therapeutics from inspecting the entity fundamentals such as Return On Asset of -0.16, shares owned by insiders of 11.68 %, and Operating Margin of (0.60) % as well as reviewing its technical indicators and probability of bankruptcy. In general, most investors encourage acquiring undervalued equities and dropping overvalued equities since, sooner or later, asset prices and their ongoing real values will blend.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Please refer to our Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Did you try this?
Run Theme Ratings Now
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any private could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
